Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]

作为全球首个获准开展商业化应用的远程手术机器人系统，图迈远程手术机器人已在中国、印度、巴西 等近10个国家获得上市批准，其应用已覆盖全球近一半人口所在区域，并已率先进入常态化、规模化临 床应用阶段。截至目前，图迈已完成远程手术近800例，覆盖20多个国家，实施成功率继续保持100%。 消息面上，2月12日，微创机器人-B发布公告，截至本公告日，集团核心产品图迈®腔镜手术机器人全 球商业化订单突破200台，覆盖近50个国家和地区，已完成商业化装机近130台。图迈商业化订单和装机 规模的再次里程碑式跃升，标志着其临床价值在全球范围内获得持续、广泛的认可，是对图迈安全性、 稳定性、可靠性的系统性认证。来自不同国家、不同医疗体系、不同专科背景的外科医生，正在以真实 而审慎的临床决策，将图迈纳入日常手术实践与长期学科建设之中。 智通财经APP获悉，微创机器人-B(02252)高开逾3%，截至发稿，涨3.24%，报26.8港元，成交额298.7万 港元。 ...

Major Events - Fuhong Hanlin (02696) received NMPA approval for the Phase I clinical trial application of HLX15-SC for the treatment of multiple myeloma [1] - Kangzheng Pharmaceutical (00867) signed an exclusive distribution agreement for the original drug Lidoderm® lidocaine gel patch [1] - MicroPort Robotics-B (02252) surpassed 200 global commercial orders for the Tumai® laparoscopic surgical robot [1] - BGO Group (08220) plans to acquire a proposal from Stephen Chow at a discount of approximately 91.79% [1] - Kogee Pharmaceuticals-B (02171) signed a strategic cooperation agreement with Shanghai Jinguang Enterprise Development to build a commercial production base for CAR-T cell therapy products in Jinshan [1] Operating Performance - China Resources Land (01109) reported total contract sales of approximately 11.65 billion yuan in January, a year-on-year increase of 0.4% [1] - Hua Hong Semiconductor (01347) announced a profit attributable to the parent company of 54.881 million USD for 2025, a year-on-year decrease of 5.6% [1] - China Coal Energy (01898) reported coal sales of 20.05 million tons in January, a year-on-year decrease of 7.3% [1] - China Metallurgical Group (01618) signed new contracts worth 73.65 billion yuan in January [1] - China Communications Construction (01800) reported new contracts worth 1.883672 trillion yuan for 2025, a year-on-year increase of 0.13% [1]

Group 1: Film Industry Initiatives - The National Film Administration and the Ministry of Commerce have organized a "Film+" consumption pilot program in 16 selected cities to enhance film-related consumption and economic development [1] - The pilot cities will focus on increasing film viewing consumption, innovating cinema experiences, expanding film derivative consumption, and creating a "Film+" consumption brand [1] - The initiative aims to extend the film industry chain and promote a healthy film consumption culture, thereby meeting the growing demand for quality life among the public [1] Group 2: Market Trends and Stock Performance - U.S. stock indices experienced significant declines, with the Dow Jones down 1.34%, S&P 500 down 1.57%, and Nasdaq down 2.03%, indicating a bearish trend in the market [2] - Major technology stocks fell sharply, with Apple down 5% and Amazon, Meta, and Tesla down over 2%, reflecting broader market concerns [2] - The Hang Seng Index ADR also dropped by 1.62%, suggesting a negative sentiment in the Hong Kong market [2] Group 3: Corporate Earnings and Forecasts - Huahong Semiconductor reported a 22.4% year-on-year increase in sales revenue, reaching approximately $660 million, but net profit decreased by 32.2% [9] - China Tongfu issued a profit warning, expecting a revenue decline of 5% to 8% and a net profit drop of 25% to 30% compared to the previous year, primarily due to decreased earnings in its nuclear medical equipment division [10] - Skyworth Group anticipates a 30% decrease in profit for the fiscal year ending December 31, 2025, attributed to the ongoing downturn in the Chinese real estate market [11] Group 4: Corporate Transactions and Developments - Chang'an Minsheng Logistics announced the sale of 16.03% of its shares by its major shareholder, Meiji Logistics, to Luhang Zhongbang, marking a significant change in ownership [7] - Micron Robotics-B reported over 200 global commercial orders for its TUMAI® laparoscopic surgical robot, indicating strong market acceptance and clinical value [8] - Bigao Group is seeking to restructure its convertible bond terms with Stephen Chow, proposing a significant discount on the share price, which may trigger a mandatory general offer [12]

在全球化布局持续加速的同时，图迈在单中心临床应用深度方面亦不断取得突破性进展。根据内部数据 统计，截至目前已完成图迈商业化装机的各国医疗机构中，单中心手术量超过百例的已有数十家，并广 泛覆盖泌尿外科、普通外科、胸外科、妇科、小儿外科、头颈外科等多个科室。 智通财经APP讯，微创机器人-B(02252)发布公告，截至本公告日，集团核心产品图迈®腔镜手术机器人 全球商业化订单突破200台，覆盖近50个国家和地区，已完成商业化装机近130台。图迈商业化订单和装 机规模的再次里程碑式跃升，标志着其临床价值在全球范围内获得持续、广泛的认可，是对图迈安全 性、稳定性、可靠性的系统性认证。来自不同国家、不同医疗体系、不同专科背景的外科医生，正在以 真实而审慎的临床决策，将图迈纳入日常手术实践与长期学科建设之中。 在已覆盖的近50个国家和地区中，订单数超5台的达12个，新兴市场代表印度、巴西、阿根廷增长强 劲，其中印度累计订单已达14台，巴西超过10台;发达国家市场持续突破，西班牙、澳大利亚等国家成 为快速增长点。图迈商业化已在全球范围内形成多区域协同共振的新格局，贯穿发展中国家新兴市场以 及发达国家成熟医疗体系。 作为全球 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，截至本公告日，本集團核心產品圖邁®腔 鏡手術機器人（「圖邁」）全球商業化訂單突破200台，覆蓋近50個國家和地區， 已完成商業化裝機近130台。圖邁商業化訂單和裝機規模的再次里程碑式躍升， 標誌著其臨床價值在全球範圍內獲得持續、廣泛的認可，是對圖邁安全性、穩 定性、可靠性的系統性認證。來自不同國家、不同醫療體系、不同專科背景的 外科醫生，正在以真實而審慎的臨床決策，將圖邁納入日常手術實踐與長期學 科建設之中。 在已覆蓋的近50個國家和地區中，訂單數超5台的達12個，新興市場代表印度、 巴西、阿根廷增長強勁，其中印度累計訂單已達14台，巴西超過10台；發達國 家市場持續突破，西班牙、澳大利亞等國家成為快速增長點。圖邁商業化已在 全球範圍內形成多區域協同共振的新格局，貫穿發展中國家新興市場以及發 達國家成熟醫療體系。 （於中華人民共和國註冊成立的股份有限公司） – 1 – ...

Investment Rating - The industry investment rating is "Positive" [1] Core Insights - The National Healthcare Security Administration issued a guideline on January 20, 2026, for pricing projects related to surgical and therapeutic auxiliary medical services, which is expected to enhance the penetration rate of surgical robots [5] - The guideline consolidates existing pricing projects into 37 items and aims to standardize pricing across provinces, facilitating the promotion of precision medical technologies in clinical settings [5] - The pricing structure for surgical robots includes three tiers based on their involvement in surgeries, which is anticipated to increase their usage in complex procedures [5] - Domestic surgical robot companies with significant surgical volume and clinical recognition are expected to benefit from industry expansion, including companies like Tianzhihang-U, Aikang Medical, Weikang Robot, and Jingfeng Medical [5] Summary by Sections Market Trends - The report highlights a recent trend in the medical and biological sector, indicating a slight decline in the market index over the past year, with a notable focus on surgical robots [2] Industry Developments - The guideline's focus on various advanced medical technologies, such as 3D printing and robotic-assisted surgeries, is expected to clarify and unify pricing standards, thereby enhancing the market acceptance of domestic surgical robots [5] Company Performance - Key companies in the surgical robot industry are showing promising operational metrics, with Tianzhihang performing over 35,000 surgeries and holding a market share exceeding 70% in domestic orthopedic robot surgeries [6] - Aikang Medical anticipates a revenue growth of approximately 110% to 120% in 2025, driven by breakthroughs in the commercialization of its robotic products [6] - Weikang Robot has reported a fivefold increase in overseas market sales compared to the previous year, indicating strong growth potential [6] - Jingfeng Medical has expanded its product reach to over 20 countries, with significant operational milestones achieved [6]

Group 1 - The company expects a revenue growth of approximately 110% to 120% for the fiscal year ending December 31, 2025, compared to the fiscal year ending December 31, 2024, primarily due to significant progress in the commercialization of its core product, the TUMAI® laparoscopic surgical robot [1] - The company has signed over 100 new orders in overseas markets, with overseas sales revenue exceeding five times that of the previous year, indicating strong global expansion momentum [1] - As of the date of the announcement, the total commercial orders for TUMAI globally exceeded 180 units, with the cumulative installed base surpassing 120 units [1] Group 2 - The company anticipates an adjusted net loss of no more than RMB 240 million for the fiscal year ending December 31, 2025, which represents a reduction of over 50% compared to the adjusted net loss of approximately RMB 482 million for the fiscal year ending December 31, 2024 [1] - The reduction in loss is attributed to rapid revenue growth and significant decreases in product costs and operating expenses due to various cost control measures [1] - The company expects a substantial narrowing of free cash flow net outflow by over 80% for the fiscal year ending December 31, 2025, to no more than RMB 70 million [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 自願性公告 本公告由上海微醫療機器人（集團）股份有限公司（「本公司」，連同其附屬公司 統稱為「本集團」）自願作出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，基於 對本集團截至2025年12月31日止年度（「報告期間」）未經審核綜合管理賬目及董 事會現時可獲得數據的初步評估及分析，董事會預期本公司報告期間的收入 較截至2024年12月31日止年度同比增長約110%至120%。該大幅躍升主要歸因於 核心產品圖邁®腔鏡手術機器人（「圖邁」）商業化取得突破性進展，銷售增長迅 猛，尤其是圖邁海外市場拓展成效顯著，全年新簽海外市場訂單逾百台，全年 海外市場銷售收入為去年的五倍以上，增速遠 ...

Core Viewpoint - The article highlights the successful commercialization and global expansion of the TUMAI® robotic surgical system, marking a significant milestone in China's medical technology innovation and its role in global healthcare [2][4]. Group 1: Commercialization Milestones - The TUMAI® robotic surgical system has officially landed in Brazil at Hospital Unimed Foz do Iguaçu, marking the 100th commercial installation globally, with over 160 cumulative orders to date [2][10]. - The rapid growth in orders from October to December 2025, from over 100 to 160+, showcases the unprecedented commercialization speed of the TUMAI® system [10]. - The TUMAI® robot has achieved a significant market presence, becoming the first domestic laparoscopic surgical robot to reach 100 commercial installations, indicating its reliability and clinical stability [2][10]. Group 2: Strategic Partnerships and Market Integration - Hospital Unimed Foz do Iguaçu represents a key part of Brazil's Unimed healthcare system, the largest cooperative healthcare system in Brazil, indicating TUMAI®'s deep integration capabilities within established healthcare frameworks [8]. - The successful installation at this flagship hospital demonstrates TUMAI®'s ability to align with procurement models, maintenance costs, and training systems, enhancing its market expansion potential in Brazil and Latin America [8][10]. - The TUMAI® robot's entry into various international markets, including partnerships with top medical institutions in countries like Belgium, Italy, and India, reflects its growing global footprint and acceptance [25][29]. Group 3: Ecosystem Development and Technological Advancements - A multi-layered robotic surgical ecosystem is forming, integrating top experts, regional medical centers, and grassroots hospitals, facilitating the widespread adoption of robotic surgery [32]. - The TUMAI® system has enabled remote surgical capabilities across various regions, including successful cross-border surgeries in the Middle East and Europe, enhancing the accessibility of high-quality surgical resources [34][41]. - The article emphasizes the importance of TUMAI®'s technological advancements and its ability to adapt to diverse regulatory and clinical environments, establishing a competitive edge in the global market [42].